Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Taylor, Ninon ^a   Grabmeier Pfistershammer, Katharina ^b   Egle, Alexander ^a   Greil, Richard ^a   Rieger, Armin ^b   Ledergerber, Bruno ^c   Oberkofler, Hannes ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASUREMENT; PATIENT MONITORING; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; TAQ POLYMERASE; TIME FACTORS; VIRAL LOAD;

EID: 84883407762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074024     Document Type: Article

References (26)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
2. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, et al. (2011) HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol 49: 292-297.
3. Damond F, Roquebert B, Benard A, Collin G, Miceli M, et al. (2007) Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 45: 3436-3438.
4. Gueudin M, Plantier JC, Lemee V, Schmitt MP, Chartier L, et al. (2007) Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 44: 500-505.
5. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, et al. (2009) Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 47: 1238-1240.
6. Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, et al. (2009) Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 47: 1543-1545.
7. Taylor N, Schmid I, Egle A, Greil R, Patsch W, et al. (2009) Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antivir Ther 14: 1189-1193.
8. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, et al. (2009) Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol 47: 889-895.
9. Foulongne V, Montes B, ot-Rousseau MN, Segondy M, (2006) Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J Clin Microbiol 44: 2963-2966.
10. Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, et al. (2012) Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. Med Microbiol Immunol.
11. Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, et al. (2010) Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr 54: 442-444.
12. Ruelle J, Debaisieux L, Vancutsem E, De BA, Delforge ML, et al. (2012) HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis 12: 100.
13. Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, et al. (2009) Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 48: 260-262.
14. Lima V, Harrigan R, Montaner JS, (2009) Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 51: 3-6.
15. Giordano M, Kelleher T, Colonno RJ, Lazzarin A, Squires K, (2006) The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol 35: 420-425.
16. Griffith BP, Mayo DR, (2006) Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J Clin Virol 35: 197-200.
17. Kran AM, Jonassen TO, Sannes M, Jakobsen K, Lind A, et al. (2009) Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J Clin Microbiol 47: 2170-2174.
18. Stosor V, Palella FJ Jr, Berzins B, Till M, Leake A, et al. (2005) Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 41: 1671-1674.
19. Garrett NJ, Apea V, Nori A, Ushiro-Lumb I, Oliver AR, et al. (2012) Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. J Clin Virol 53: 354-355.
20. Wojewoda CM, Spahlinger T, Harmon ML, Schnellinger B, Li Q, et al. (2013) Comparison of Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 (CAP/CTM v2.0) with other real-time PCR assays in HIV-1 monitoring and follow-up of low-level viral loads. J Virol Methods 187: 1-5.
21. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, et al. (2012) Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 205: 1230-1238.
22. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, et al. (2012) Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54: 724-732.
23. Ho DD, (1998) Toward HIV eradication or remission: the tasks ahead. Science 280: 1866-1867.
24. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
25. Nettles RE, Kieffer TL, (2006) Update on HIV-1 viral load blips. Curr Opin HIV AIDS 1: 157-161.
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, 2011: 1-166. http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/5/plasma-hiv-rna-testing. Accessed April 28, 2013.